Advances in the treatment of invasive fungal disease.
PLoS Pathog
; 19(5): e1011322, 2023 05.
Article
in English
| MEDLINE | ID: covidwho-2320880
ABSTRACT
With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality. The World Health Organization (WHO) recently released the first-ever fungal priority pathogens list including 19 fungal pathogens, considering the perceived public health importance. Most of the pathogenic fungi are opportunistic and cause diseases in patients under immunocompromised conditions such as HIV infection, cancer, chemotherapy, transplantation, and immune suppressive drug therapy. Worryingly, the morbidity and mortality caused by IFDs are continuously on the rise due to the limited available antifungal therapies, the emergence of drug resistance, and the increase of population that is vulnerable to IFDs. Moreover, the COVID-19 pandemic worsened IFDs as a globe health threat as it predisposes the patients to secondary life-threatening fungi. In this mini-review, we provide a perspective on the advances and strategies for combating IFDs with antifungal therapies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
HIV Infections
/
Invasive Fungal Infections
/
COVID-19
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
PLoS Pathog
Year:
2023
Document Type:
Article
Affiliation country:
Journal.ppat.1011322
Similar
MEDLINE
...
LILACS
LIS